Navigation Links
Genzyme Reports Strong Second-Quarter Growth
Date:7/23/2008

icipated global demand for Myozyme. Product supply in 2009 is expected to be particularly tight until the Belgium plant is approved.

Genzyme's other treatments for lysosomal storage disorders also continue to experience strong, double-digit growth. Second-quarter Cerezyme(R) (imiglucerase for injection) sales rose 13 percent to $319.4 million, compared with $283.0 million in the previous second quarter. Sales of Fabrazyme(R) (agalsidase beta) grew 21 percent, rising to $126.6 million from $104.3 million. Sales of Aldurazyme(R) (laronidase) increased 33 percent to $38.8 million, compared with $29.1 million in the second quarter last year when the product's sales were recorded under the joint venture with BioMarin Pharmaceutical Inc.

The company also reported preliminary results from a Phase 2 trial of its investigational oral therapy for Gaucher disease Genz-112638. The results were consistent with those observed for patients beginning enzyme replacement therapy, and they highlight the potential of this compound to provide a convenient treatment alternative for patients and a broader range of treatment options for physicians. Genzyme is developing protocols for two Phase 3 trials that it expects to initiate early next year.

Sales of Thyrogen(R) (thyrotropin alfa for injection) remained strong, increasing 34 percent to $39.4 million from $29.5 million. The use of Thyrogen in ablation procedures is contributing to the product's growth in the United States, while its growth in Europe is being driven by increasing diagnosis of thyroid cancer and its international adoption is being driven by expansion into new geographic markets.

Within the Renal business, sales of sevelamer therapies Renagel(R) (sevelamer hydrochloride) and Renvela grew 16 percent to $168.6 million from $144.9 million in the second quarter last year. Genzyme launched Renvela in the United States in March, and the product is now included in more than 85 percent of health plan f
'/>"/>

SOURCE Genzyme Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease
2. Genzyme Begins Major Expansion of Boston Manufacturing Facility
3. Genzyme Affirms Purchase Price for Bioenvision at $5.60 Per Outstanding Share
4. Genzyme Receives Approval to Market Elaprase(R) in Japan
5. Genzyme Recognized by Scientists as a Top Employer
6. Genzyme to Participate in FDA Advisory Committee Meeting on the Use of Phosphate Binders in Chronic Kidney Disease
7. FDA Approves Genzymes Renvela(TM) for Dialysis Patients
8. Genzyme Launches Cholestagel(R) in Europe
9. BioVex Appoints Genzyme Executive, Jan van Heek, as Chairman of the Board of Directors
10. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
11. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014  Pomerantz LLP is investigating claims on behalf ... "Company") (NASDAQ: IPXL).  Such investors are advised to contact ... or 888-476-6529, ext. 237. The investigation concerns ... have violated Sections 10(b) and 20(a) of the Securities ... 29, 2014, Impax Laboratories, Inc. (the "Company") issued a ...
(Date:7/29/2014)... 29, 2014 A new report ... (types, applications and geography) - Size, Share, Global Trends, ... and Forecast, 2013 - 2020", suggests that the global ... by 2020 registering a CAGR of 11.1% from 2014 ... by the electro surgical devices in operative procedures by ...
(Date:7/29/2014)... 2014 Philadelphia’s newest entrepreneurial incubation space is ... start. The Innovation Center @3401 , a collaborative effort ... Science Center to help attract and nurture start-up businesses ... 28. , The Innovation Center @3401 (ic@3401), ... Streets, is the new home of DreamIt Ventures ...
(Date:7/29/2014)... July 29, 2014  United Therapeutics Corporation (NASDAQ: ... financial results for the second quarter ended ... shows that our medicines are reaching increasing ... hypertension (PAH)," said Martine Rothblatt, Ph.D., United ... commercial launch this quarter of our extended-release ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 2Global Surgical Equipment Market is expected to reach $12.1 billion by 2020 - Allied Market Research 3Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13
... Toronto, Ontario - Cedara Software , a ... of medical software technologies, has released a new version ... toolkit, MergeCOM-3. , ,The product is a software development ... and supports flexible DICOM connectivity for software applications. , ...
... into the third year of their Sarbanes-Oxley ... is a good time to pause and reflect on ... on good internal control practices, I hear from hundreds ... how painful implementing 404 has become for their companies. ...
... officials may not be saying it, but they are frightened ... deadly avian flu virus begins quietly in scattered areas of ... on it - with substantial harm done to public health ... one that is exacerbated by the lack of an electronic ...
Cached Biology Technology:The Big Picture of SOX 404 2The Big Picture of SOX 404 3The Big Picture of SOX 404 4UW compound counters Avian flu 2UW compound counters Avian flu 3
(Date:7/29/2014)... study from UC San Francisco is the first to ... overtime and accelerate cellular aging, these negative effects may ... sleeping well. , "The study participants who exercised, ... than the ones who didn,t maintain healthy lifestyles, even ... author Eli Puterman, PhD, assistant professor in the department ...
(Date:7/28/2014)... University of Arizona has sequenced the complete genome of ... and agriculturalists, understanding of the growing patterns of African ... rice varieties that are better able to cope with ... , The paper, "The genome sequence of African rice ... was published online in Nature Genetics on ...
(Date:7/28/2014)... have pinpointed a mechanism in part of the brain that ... it to both type 1 and type 2 diabetes. The ... Proceedings of the National Academies of Sciences . , ... a part of the hypothalamus known as the ventromedial nucleus ... glucose levels in the blood," said lead author Sabrina Diano, ...
Breaking Biology News(10 mins):Healthy lifestyle may buffer against stress-related cell aging, study says 2Generating a genome to feed the world: UA-led team sequences African rice 2Generating a genome to feed the world: UA-led team sequences African rice 3Generating a genome to feed the world: UA-led team sequences African rice 4Glucose 'control switch' in the brain key to both types of diabetes 2
... dayand starting this week, they will be part of a multinational ... mines left over from as long ago as the First and ... naval exercises in the Baltic Sea this year, where more than ... all part of a day,s work for U.S. Navy divers, who ...
... in air pollution were associated with changes in biomarkers of ... as measures of cardiovascular physiology in healthy young persons, according ... JAMA, a theme issue on Global Health. ... but the mechanisms by which air pollution leads to CVD ...
... A review of studies reporting estimates of the ... malaria over the past 20 years suggests that a ... women attending antenatal (before birth) facilities in sub-Saharan Africa, ... published in the May 16 issue of JAMA ...
Cached Biology News:Undersea warriors, undersea medicine: The future force 2Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 2Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 3Air pollution level changes in Beijing linked with biomarkers of cardiovascular disease 4Considerable prevalence of both malaria, STIs exist among pregnant women in sub-Saharan Africa 2
Multidrop DW is a high-speed automated dispenser for Deep Well plates, 1.1 ml test tubes and 96-well plates. Designed for accuracy and precision, the Multidrop DW dispenses up to eight different reag...
ma. plate stack height 70mm...
... Thermal Cycler (MBS) is a ... medium to high throughput PCR. ... latest in satellite block technology, ... control, resulting in a system ...
45° Fixed Angle Rotor for use in the IEC Centra CL2, Centra CL3/CL3R, HN-SII, and the Centra-MP4/MP4R....
Biology Products: